Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both ...

Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update

Preliminary full year 2025 net revenues of $655 million and fourth quarter net revenues of $174 million Novocure to present at the 44th Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PST ...
Le Lézard

Ferring Pharmaceuticals and Theralase® Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer

Ferring Pharmaceuticals and Theralase® Technologies Inc. are pleased to announce that they have entered into a collaborative clinical development agreement ("Agreement") on January 9, 2026. The ...

Johnson & Johnson: RYBREVANT (amivantamab-vmjw) longer-term results show promising and durable responses in difficult-to-treat colorectal cancer

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...